The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)

Gerd Brunner; Eric Y. Yang; Anirudh Kumar; Wensheng Sun; Salim S. Virani; Smita I. Negi; Tyler Murray; Peter H. Lin; Ron C. Hoogeveen; Changyi Chen; Jing Fei Dong; Panagiotis Kougias; Addison Taylor; Alan B. Lumsden; Vijay Nambi; Christie M. Ballantyne; Joel D. Morrisett

doi:10.1016/j.atherosclerosis.2013.09.034

The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)

Gerd Brunner, Eric Y. Yang, Anirudh Kumar, Wensheng Sun, Salim S. Virani, Smita I. Negi, Tyler Murray, Peter H. Lin, Ron C. Hoogeveen, Changyi Chen, Jing Fei Dong, Panagiotis Kougias, Addison Taylor, Alan B. Lumsden, Vijay Nambi, Christie M. Ballantyne, Joel D. Morrisett

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Methods: A total of 102 patients were randomized to either mono-therapy with simvastatin (40mg daily) or triple-therapy with simvastatin (40mg daily), extended-release niacin (1500mg daily), and ezetimibe (10mg daily). MRI was performed at baseline and 6, 12, and 24 months. SFA wall, lumen, and total vessel volumes were quantified. MRI-derived SFA parameters and lipids were analyzed with multilevel models and nonparametric tests, respectively. Results: Baseline characteristics did not differ between mono and triple-therapy groups, except for ethnicity ( p=0.02). SFA wall, lumen, and total vessel volumes increased non-significantly for both groups between baseline and 24-months. Non-high-density lipoprotein cholesterol was significantly reduced at 12 months with triple-therapy compared with mono-therapy ( p=0.01). Conclusion: No significant differences were observed between mono-therapy using simvastatin and triple-therapy with simvastatin, extended-release niacin, and ezetimibe for 24-month changes in SFA wall, lumen, and total vessel volumes. Clinical Trial Registration Information: NCT00687076; Link: http://clinicaltrials.gov/ct2/show/. NCT00687076.

Original language	English (US)
Pages (from-to)	371-377
Number of pages	7
Journal	Atherosclerosis
Volume	231
Issue number	2
DOIs	https://doi.org/10.1016/j.atherosclerosis.2013.09.034
State	Published - Dec 2013

Keywords

ABI
Atherosclerosis
ICC
Lipids
Magnetic resonance imaging
MRI
PAD
PDW
Peripheral artery disease
SFA
T1W
T2W

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.atherosclerosis.2013.09.034

Cite this

Brunner, G., Yang, E. Y., Kumar, A., Sun, W., Virani, S. S., Negi, S. I., Murray, T., Lin, P. H., Hoogeveen, R. C., Chen, C., Dong, J. F., Kougias, P., Taylor, A., Lumsden, A. B., Nambi, V., Ballantyne, C. M., & Morrisett, J. D. (2013). The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis, 231(2), 371-377. https://doi.org/10.1016/j.atherosclerosis.2013.09.034

Brunner, G, Yang, EY, Kumar, A, Sun, W, Virani, SS, Negi, SI, Murray, T, Lin, PH, Hoogeveen, RC, Chen, C, Dong, JF, Kougias, P, Taylor, A, Lumsden, AB, Nambi, V, Ballantyne, CM & Morrisett, JD 2013, 'The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)', Atherosclerosis, vol. 231, no. 2, pp. 371-377. https://doi.org/10.1016/j.atherosclerosis.2013.09.034

@article{c6dcc31409354bc5aaf807c34c8578b6,

title = "The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)",

abstract = "Methods: A total of 102 patients were randomized to either mono-therapy with simvastatin (40mg daily) or triple-therapy with simvastatin (40mg daily), extended-release niacin (1500mg daily), and ezetimibe (10mg daily). MRI was performed at baseline and 6, 12, and 24 months. SFA wall, lumen, and total vessel volumes were quantified. MRI-derived SFA parameters and lipids were analyzed with multilevel models and nonparametric tests, respectively. Results: Baseline characteristics did not differ between mono and triple-therapy groups, except for ethnicity ( p=0.02). SFA wall, lumen, and total vessel volumes increased non-significantly for both groups between baseline and 24-months. Non-high-density lipoprotein cholesterol was significantly reduced at 12 months with triple-therapy compared with mono-therapy ( p=0.01). Conclusion: No significant differences were observed between mono-therapy using simvastatin and triple-therapy with simvastatin, extended-release niacin, and ezetimibe for 24-month changes in SFA wall, lumen, and total vessel volumes. Clinical Trial Registration Information: NCT00687076; Link: http://clinicaltrials.gov/ct2/show/. NCT00687076.",

keywords = "ABI, Atherosclerosis, ICC, Lipids, Magnetic resonance imaging, MRI, PAD, PDW, Peripheral artery disease, SFA, T1W, T2W",

author = "Gerd Brunner and Yang, \{Eric Y.\} and Anirudh Kumar and Wensheng Sun and Virani, \{Salim S.\} and Negi, \{Smita I.\} and Tyler Murray and Lin, \{Peter H.\} and Hoogeveen, \{Ron C.\} and Changyi Chen and Dong, \{Jing Fei\} and Panagiotis Kougias and Addison Taylor and Lumsden, \{Alan B.\} and Vijay Nambi and Ballantyne, \{Christie M.\} and Morrisett, \{Joel D.\}",

note = "Funding Information: This work was supported by NIH grants R01HL63090, R01HL075824, and R01 HL085769 and by funding from the Division of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas. Merck \& Co. and Abbott Laboratories supplied the study medication (simvastatin, ezetimibe, and niacin). Merck and Abbott had no input in the study design, analysis, or presentation of results. Dr. Yang received grant support through the AHA South Central Affiliate Postdoctoral Fellowship Grant (ID: 2010POST4250013). Dr. Virani is supported by a Department of Veterans Affairs Health Services Research and Development Service (HSR\&D) Career Development Award (CDA-09-028). Dr. Nambi was supported by an NIH Career Development Award (K23HL096893). Funding Information: This work was supported by NIH grants R01HL63090 , R01HL075824 , and R01 HL085769 and by funding from the Division of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas . The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. ",

year = "2013",

month = dec,

doi = "10.1016/j.atherosclerosis.2013.09.034",

language = "English (US)",

volume = "231",

pages = "371--377",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)

AU - Brunner, Gerd

AU - Yang, Eric Y.

AU - Kumar, Anirudh

AU - Sun, Wensheng

AU - Virani, Salim S.

AU - Negi, Smita I.

AU - Murray, Tyler

AU - Lin, Peter H.

AU - Hoogeveen, Ron C.

AU - Chen, Changyi

AU - Dong, Jing Fei

AU - Kougias, Panagiotis

AU - Taylor, Addison

AU - Lumsden, Alan B.

AU - Nambi, Vijay

AU - Ballantyne, Christie M.

AU - Morrisett, Joel D.

N1 - Funding Information: This work was supported by NIH grants R01HL63090, R01HL075824, and R01 HL085769 and by funding from the Division of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas. Merck & Co. and Abbott Laboratories supplied the study medication (simvastatin, ezetimibe, and niacin). Merck and Abbott had no input in the study design, analysis, or presentation of results. Dr. Yang received grant support through the AHA South Central Affiliate Postdoctoral Fellowship Grant (ID: 2010POST4250013). Dr. Virani is supported by a Department of Veterans Affairs Health Services Research and Development Service (HSR&D) Career Development Award (CDA-09-028). Dr. Nambi was supported by an NIH Career Development Award (K23HL096893). Funding Information: This work was supported by NIH grants R01HL63090 , R01HL075824 , and R01 HL085769 and by funding from the Division of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas . The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.

PY - 2013/12

Y1 - 2013/12

N2 - Methods: A total of 102 patients were randomized to either mono-therapy with simvastatin (40mg daily) or triple-therapy with simvastatin (40mg daily), extended-release niacin (1500mg daily), and ezetimibe (10mg daily). MRI was performed at baseline and 6, 12, and 24 months. SFA wall, lumen, and total vessel volumes were quantified. MRI-derived SFA parameters and lipids were analyzed with multilevel models and nonparametric tests, respectively. Results: Baseline characteristics did not differ between mono and triple-therapy groups, except for ethnicity ( p=0.02). SFA wall, lumen, and total vessel volumes increased non-significantly for both groups between baseline and 24-months. Non-high-density lipoprotein cholesterol was significantly reduced at 12 months with triple-therapy compared with mono-therapy ( p=0.01). Conclusion: No significant differences were observed between mono-therapy using simvastatin and triple-therapy with simvastatin, extended-release niacin, and ezetimibe for 24-month changes in SFA wall, lumen, and total vessel volumes. Clinical Trial Registration Information: NCT00687076; Link: http://clinicaltrials.gov/ct2/show/. NCT00687076.

AB - Methods: A total of 102 patients were randomized to either mono-therapy with simvastatin (40mg daily) or triple-therapy with simvastatin (40mg daily), extended-release niacin (1500mg daily), and ezetimibe (10mg daily). MRI was performed at baseline and 6, 12, and 24 months. SFA wall, lumen, and total vessel volumes were quantified. MRI-derived SFA parameters and lipids were analyzed with multilevel models and nonparametric tests, respectively. Results: Baseline characteristics did not differ between mono and triple-therapy groups, except for ethnicity ( p=0.02). SFA wall, lumen, and total vessel volumes increased non-significantly for both groups between baseline and 24-months. Non-high-density lipoprotein cholesterol was significantly reduced at 12 months with triple-therapy compared with mono-therapy ( p=0.01). Conclusion: No significant differences were observed between mono-therapy using simvastatin and triple-therapy with simvastatin, extended-release niacin, and ezetimibe for 24-month changes in SFA wall, lumen, and total vessel volumes. Clinical Trial Registration Information: NCT00687076; Link: http://clinicaltrials.gov/ct2/show/. NCT00687076.

KW - ABI

KW - Atherosclerosis

KW - ICC

KW - Lipids

KW - Magnetic resonance imaging

KW - MRI

KW - PAD

KW - PDW

KW - Peripheral artery disease

KW - SFA

KW - T1W

KW - T2W

UR - https://www.scopus.com/pages/publications/84888105745

UR - https://www.scopus.com/inward/citedby.url?scp=84888105745&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2013.09.034

DO - 10.1016/j.atherosclerosis.2013.09.034

M3 - Article

C2 - 24267254

AN - SCOPUS:84888105745

SN - 0021-9150

VL - 231

SP - 371

EP - 377

JO - Atherosclerosis

JF - Atherosclerosis

IS - 2

ER -

The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this